BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25635530)

  • 21. Dose-limiting stomatitis associated with ibrutinib therapy: a case series.
    Vigarios E; Beylot-Barry M; Jegou MH; Oberic L; Ysebaert L; Sibaud V
    Br J Haematol; 2019 May; 185(4):784-788. PubMed ID: 30408164
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.
    Ahn IE; Basumallik N; Tian X; Soto S; Wiestner A
    Blood; 2019 May; 133(22):2452-2455. PubMed ID: 30917955
    [No Abstract]   [Full Text] [Related]  

  • 23. Probable Invasive Pulmonary Cryptococcosis and Possible Cryptococcal Empyema in CLL Treated With Frontline Ibrutinib.
    Koehler AB; Vijayvargiya P; Ding W
    Mayo Clin Proc; 2019 May; 94(5):915-917. PubMed ID: 31054610
    [No Abstract]   [Full Text] [Related]  

  • 24. Different clonal origin of B-cell populations of chronic lymphocytic leukemia and large-cell lymphoma in Richter's syndrome.
    Matolcsy A; Casali P; Knowles DM
    Ann N Y Acad Sci; 1995 Sep; 764():496-503. PubMed ID: 7486574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
    Tobinai K; Uchida T; Fukuhara N; Nishikawa T
    Int J Hematol; 2019 Mar; 109(3):366-368. PubMed ID: 30623356
    [No Abstract]   [Full Text] [Related]  

  • 26. Malakoplakia of the Urinary Bladder in a Patient with Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: A Case Report.
    Sachanas S; Pangalis GA; Karouzakis P; Koulieris E; Moschogiannis M; Kalpadakis C; Yiakoumis X; Rontogianni D
    Anticancer Res; 2016 Sep; 36(9):4759-62. PubMed ID: 27630324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib.
    Koshiishi M; Odate T; Nakagawa Y; Suzuki J; Kumagai T; Kawashima I; Yamamoto T; Nakajima K; Tanaka M; Oishi N; Kondo T; Kirito K
    Intern Med; 2021 Oct; 60(20):3305-3308. PubMed ID: 33896865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
    Poole A; Girard N; Clayton F; Tantravahi SK
    Leuk Lymphoma; 2017 May; 58(5):1258-1261. PubMed ID: 27750463
    [No Abstract]   [Full Text] [Related]  

  • 29. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Vitale C; Ahn IE; Sivina M; Ferrajoli A; Wierda WG; Estrov Z; Konoplev SN; Jain N; O'Brien S; Farooqui M; Keating MJ; Wiestner A; Burger JA
    Haematologica; 2016 Jun; 101(6):e254-8. PubMed ID: 27013651
    [No Abstract]   [Full Text] [Related]  

  • 30. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
    Titus-Rains KS; Brown JN; Hammond JM
    J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
    Glavey S; Quinn J; McCloy M; Sargent J; McCartney Y; Catherwood M; Marafioti T; Leader M; Murphy P; Thornton P
    Eur J Haematol; 2017 Oct; 99(4):378-380. PubMed ID: 28561533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
    Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
    Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus infection in Richter's transformation.
    Ansell SM; Li CY; Lloyd RV; Phyliky RL
    Am J Hematol; 1999 Feb; 60(2):99-104. PubMed ID: 9929100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased lymphocyte cell size with blastoid morphology associated with splenic rupture following cessation of ibrutinib.
    Porpaczy E; Skrabs C; Schwarzinger I; Augustin D; Thalhammer R; Jaeger U
    Br J Haematol; 2018 May; 181(4):431. PubMed ID: 29479671
    [No Abstract]   [Full Text] [Related]  

  • 35. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT.
    Bruzzi JF; Macapinlac H; Tsimberidou AM; Truong MT; Keating MJ; Marom EM; Munden RF
    J Nucl Med; 2006 Aug; 47(8):1267-73. PubMed ID: 16883004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).
    Jamroziak K; Szymczyk A; Hus M; Wojciechowska M; Knopinska-Posłuszny W; Hołojda J; Hałaburda K; Warzocha K; Iskierka-Jażdżewska E
    Eur J Haematol; 2018 Apr; 100(4):389-391. PubMed ID: 29243346
    [No Abstract]   [Full Text] [Related]  

  • 37. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
    Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
    Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
    [No Abstract]   [Full Text] [Related]  

  • 38. Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.
    Peri AM; Bisi L; Cappelletti A; Colella E; Verga L; Borella C; Foresti S; Migliorino GM; Gori A; Bandera A
    Clin Microbiol Infect; 2018 Jul; 24(7):785-786. PubMed ID: 29427802
    [No Abstract]   [Full Text] [Related]  

  • 39. Richter's transformation of chronic lymphocytic leukemia.
    Giardino AA; O'Regan K; Jagannathan JP; Elco C; Ramaiya N; Lacasce A
    J Clin Oncol; 2011 Apr; 29(10):e274-6. PubMed ID: 21220587
    [No Abstract]   [Full Text] [Related]  

  • 40. Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?
    Sachanas S; Pangalis GA; Moschogiannis M; Yiakoumis X; Koulieris E; Tsirkinidis P; Kalpadakis C; Rontogianni D
    Anticancer Res; 2017 Jun; 37(6):3277-3280. PubMed ID: 28551676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.